- The US has launched antidumping and countervailing duty investigations against Indonesian and Malaysian fatty acid exporters, with alleged dumping margins up to 170%.
- The petition comes from a US industry under financial pressure — the petitioner recently refinanced $900M in debt, and another major producer is shutting its plant.
- Even if the case ultimately fails, it has the potential to disrupt trade flows for 12–18 months through provisional duties and cash deposit requirements.
The United States has launched antidumping and countervailing duty investigations into imports of fatty acids from Indonesia and Malaysia. The case was set off in January by Vantage Specialty Chemicals, an US oleochemical producer. If successful, this could result in even bigger tariffs on stearic acid, oleic acid, palm fatty acid distillate, palm kernel fatty acid entering the US.
For those who need a quick reminder: dumping is when a producer exports at a price lower than the price it charges in its home market. Antidumping measures are tariffs that counteract that.
The dumping margins are big: 18 to 70 percent for Indonesia, 60 to 170 percent for Malaysia. Earlier this month the US International Trade Commission gave a preliminary green light for the case to go ahead.
But it is worth asking a basic question: is the US fatty acid industry genuinely being injured by unfairly traded imports, or is it struggling to compete? After all, this has been the case in Europe for some time.
Vantage Specialty Chemicals is not a scrappy domestic manufacturer fighting for survival against foreign predators. It is a portfolio company of H.I.G. Capital, one of America’s largest private equity firms. H.I.G. acquired Vantage in a leveraged buyout in 2017, and in September 2025, just months before the petition was filed, Vantage refinanced its outstanding debt through a $900 million direct lending package, replacing its existing bank-arranged debt.
That is a company carrying big debt. When margins come under pressure, PE-backed companies have a well-documented playbook: cut costs, restructure, or litigate.
Trade remedy petitions work in this scenario. They are relatively cheap, put impose immediate costs on imports (an unsuccessful case disrupts trade for 12 to 18 months), and give long-term tariff protection if successful. For a company under pressure, AD/CVD petition is a rational financial strategy.
Vantage is not the only US fatty acid producer under strain. PMC Biogenix, another major US oleochemical producer — and one of the companies Commerce polled for industry support in this very investigation — filed a WARN Act notice on 3 March 2026, announcing the permanent closure of its Memphis, Tennessee fatty acid and oleochemical plant. The closure eliminates 172 jobs.
Chemical & Engineering News reported last month that business conditions for US chemical companies have been tough.US stalwart Dow announced 4,500 job cuts.
Is the US industry undergoing structural adjustment, just as has happened in Europe?
The Indonesian Government response has been swift with a consultation paper on the CVD docket (C-560-849), contesting the Petition’s subsidy allegations.
The GOI paper addresses all fifteen domestic subsidy programs alleged by the Petitioner, plus six “transnational subsidy” allegations involving the Government of China. Its central argument: the Petition fails to meet the basic evidentiary standard required under WTO rules to justify an investigation.
There are plenty of things the petitioners get wrong. For example, the Petitioner calls Indonesia’s Oil Palm Plantation Fund (BPDPKS) a “Biodiesel Subsidy Fund” — a term that does not exist in Indonesian law. But it also makes an assumption that the Indonesian palm oil industry is completely vertically integrated — an assumption the GOI calls “entirely baseless.”
In addition, there’s an argument that Indonesia provides natural gas at below-market rates. The GOI points out that Indonesia’s regulated gas ceiling is US$6–7/MMBTU, while US Henry Hub prices during the same period ranged from US$1.60 to US$4.12/MMBTU. In other words, Indonesian producers are paying more for gas than their American competitors.
And for the trade wonks, the petition alleges that Chinese government financing to Indonesian operations constitutes a countervailable subsidy attributable to Indonesia. The GOI’s response is categorical: Indonesia cannot be held responsible for another country’s policies, citing a WTO case where the EU could not attribute Chinese-origin financial contributions to Indonesia based solely on a finding of “inducement.”
The timing of this case raises broader questions about the coherence of US trade policy toward Indonesia.
As we know, just nine days before the fatty acids petition was filed — Indonesia and the United States signed a bilateral Agreement on Reciprocal Tariffs (ART). Indonesia made concessions to reach that agreement, in the explicit expectation that it would stabilise the trade relationship.
This isn’t an infraction, just a discomfort. After all, the EU is doing very similar things.
At the same time, the fatty acids case does not exist in a vacuum. The Trump Administration has launched the most expansive Section 301 investigation architecture in history — covering overcapacity across sixteen economies (including Indonesia) and forced labour across sixty.
The analytical framework underpinning those investigations treats government support for industrial capacity expansion as inherently trade-distorting, regardless of whether the support confers a benefit in the traditional subsidy sense. If Commerce finds in the CVD investigation that Indonesia’s export levy constitutes a provision of goods for less than adequate remuneration, that finding could feed directly into USTR’s broader Section 301 analysis of Indonesian oleochemical capacity.
The CVD preliminary determination is due in May, and the AD preliminary determination follows late July. If both proceed, duties will begin to stack — first CVD, then AD — requiring cash deposits from US importers of Indonesian and Malaysian fatty acids.
The GOI’s response is correct, but the real defence will be built in the questionnaire responses, the cost data, and the legal arguments that follow.